Abstract
Selective Estrogen Receptor Modulators (SERMs) have been developed, but the selectivity towards the subtypes (ERα or ERβ) is not well understood. Based on three-dimensional structural properties of ligand binding domains, a model that takes into account this aspect was developed via molecular interaction fields and consensus principal component analysis (GRID/CPCA).
Keywords: ER subtypes, consensus PCA, selective estrogen receptor modulators, SERM, ligand binding domain, key interactions
Letters in Drug Design & Discovery
Title: Estrogen Receptor: Structural Differences and Potential Implications on Selectivity Examined by the GRID/CPCA Approach
Volume: 5 Issue: 3
Author(s): I. R.A. de Menezes, A. Leitao and C. A. Montanari
Affiliation:
Keywords: ER subtypes, consensus PCA, selective estrogen receptor modulators, SERM, ligand binding domain, key interactions
Abstract: Selective Estrogen Receptor Modulators (SERMs) have been developed, but the selectivity towards the subtypes (ERα or ERβ) is not well understood. Based on three-dimensional structural properties of ligand binding domains, a model that takes into account this aspect was developed via molecular interaction fields and consensus principal component analysis (GRID/CPCA).
Export Options
About this article
Cite this article as:
de Menezes R.A. I., Leitao A. and Montanari A. C., Estrogen Receptor: Structural Differences and Potential Implications on Selectivity Examined by the GRID/CPCA Approach, Letters in Drug Design & Discovery 2008; 5 (3) . https://dx.doi.org/10.2174/157018008784083947
DOI https://dx.doi.org/10.2174/157018008784083947 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies
Current Angiogenesis (Discontinued) Reduced NGF Secretion by HT-29 Human Colon Cancer Cells Treated with a GRPR Antagonist
Protein & Peptide Letters Ruthenium Complexes as Anticancer Agents
Current Medicinal Chemistry NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Recent Advances in Understanding of Kinetic Interplay Between Phase II Metabolism and Efflux Transport
Current Drug Metabolism The Use of Methylphenidate for Physical and Psychological Symptoms in Cancer Patients: A Review
Current Drug Targets Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Low Concentration of Salinomycin Prevents Regrowth and Partially Depletes Human Glioma Cells Surviving High Concentrations of Alkylating Agents
Clinical Cancer Drugs γ-Hydroxybutenolide Containing Marine Natural Products and Their Synthesis: A Review
Current Organic Chemistry Editorial (Thematic Issue: Personalized Cancer Treatment)
Current Molecular Pharmacology α(N)-Heterocyclic Thiosemicarbazones: Iron Chelators that are Promising for Revival of Gallium in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Kruppel-Like Factors 4 and 5: Unity in Diversity
Current Genomics The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis
Current Cancer Drug Targets Application of Phage Display Technology to Cancer Research
Current Pharmaceutical Biotechnology Lipids as Biomarkers of Cancer and Bacterial Infections
Current Medicinal Chemistry The Anticancer Effect of Sanguinarine: A Review
Current Pharmaceutical Design Natural Products as Aromatase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Pleiotropic Effects of Omega-3 Fatty Acids
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?
Current Molecular Medicine Susceptibility Risk Alleles of -238G/A, -308G/A and -1031T/C Promoter Polymorphisms of TNF-α Gene to Uterine Leiomyomas
Recent Advances in DNA & Gene Sequences (Discontinued)